Pharming Group N.V. (PHAR) 10-Year Financial Performance & Capital Metrics

PHAR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutPharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Show more

Revenue $297M +21.1%
EBITDA $7M -29.3%
Net Income -$12M -12.3%
EPS (Diluted) -0.17 -21.4%
Gross Margin 88.09% -1.8%
EBITDA Margin 2.51% -41.7%
Operating Margin -2.9% -32.1%
Net Margin -3.98% +7.3%
ROE -5.38% -8.1%
ROIC -2.13% -29.9%
Debt/Equity 0.51 -35.2%
Interest Coverage -0.99 -9.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.7%

5Y9.43%

3Y14.33%

TTM26.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM102.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM103.76%

ROCE

10Y Avg9.7%

5Y Avg8.35%

3Y Avg0.41%

Latest-2.42%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.84M	16.69M	107.52M	154.58M	189.39M	212.17M	198.87M	205.62M	245.32M	297.2M
Revenue Growth %	-0.54%	0.41%	5.44%	0.44%	0.23%	0.12%	-0.06%	0.03%	0.19%	0.21%
Cost of Goods Sold+	5.25M	4.93M	14.93M	25.37M	23.93M	23.54M	21.14M	17.56M	25.21M	35.4M
COGS % of Revenue	0.44%	0.3%	0.14%	0.16%	0.13%	0.11%	0.11%	0.09%	0.1%	0.12%
Gross Profit+	6.59M	11.77M	92.59M	129.2M	165.46M	188.63M	177.73M	188.06M	220.1M	261.8M
Gross Margin %	0.56%	0.7%	0.86%	0.84%	0.87%	0.89%	0.89%	0.91%	0.9%	0.88%
Gross Profit Growth %	-0.69%	0.79%	6.87%	0.4%	0.28%	0.14%	-0.06%	0.06%	0.17%	0.19%
Operating Expenses+	20.62M	23.91M	66.3M	85.74M	97.22M	112.38M	164.17M	169.83M	225.49M	270.42M
OpEx % of Revenue	1.74%	1.43%	0.62%	0.55%	0.51%	0.53%	0.83%	0.83%	0.92%	0.91%
Selling, General & Admin	5.28M	8.07M	44.86M	53.49M	55.88M	65M	48.13M	68.85M	87.5M	99.22M
SG&A % of Revenue	0.45%	0.48%	0.42%	0.35%	0.3%	0.31%	0.24%	0.33%	0.36%	0.33%
Research & Development	15.5M	16.18M	22.38M	33.04M	31.79M	38.52M	70.37M	52.53M	68.91M	83.15M
R&D % of Revenue	1.31%	0.97%	0.21%	0.21%	0.17%	0.18%	0.35%	0.26%	0.28%	0.28%
Other Operating Expenses	-147K	-335K	-790K	-684K	9.55M	8.86M	45.67M	48.44M	69.08M	88.06M
Operating Income+	-14.03M	-12.14M	26.29M	43.46M	68.25M	76.26M	13.56M	18.23M	-5.39M	-8.62M
Operating Margin %	-1.19%	-0.73%	0.24%	0.28%	0.36%	0.36%	0.07%	0.09%	-0.02%	-0.03%
Operating Income Growth %	-5.01%	0.14%	3.17%	0.65%	0.57%	0.12%	-0.82%	0.34%	-1.3%	-0.6%
EBITDA+	-14.75M	-11.34M	30.38M	50.96M	74.05M	84.57M	33.17M	31.42M	10.54M	7.45M
EBITDA Margin %	-1.25%	-0.68%	0.28%	0.33%	0.39%	0.4%	0.17%	0.15%	0.04%	0.03%
EBITDA Growth %	-4.97%	0.23%	3.68%	0.68%	0.45%	0.14%	-0.61%	-0.05%	-0.66%	-0.29%
D&A (Non-Cash Add-back)	-716.11K	795.09K	4.1M	7.5M	5.8M	8.31M	19.61M	13.19M	15.93M	16.07M
EBIT	-9.9M	-14.67M	-80.43M	17.35M	65.66M	50.04M	29.17M	20.34M	-6.05M	245K
Net Interest Income+	-851.68K	-6.38M	-56.53M	-16.35M	-12.22M	-5.3M	-6.12M	-5.27M	-2.44M	-3.02M
Interest Income	130.1K	5.26K	3.6K	20.59K	1.13M	715K	52.92K	85K	3.53M	5.72M
Interest Expense	981.78K	3.77M	21.28M	16.37M	13.35M	5.94M	6.18M	5.36M	5.96M	8.74M
Other Income/Expense	4.07M	-6.31M	-129.09M	-37.01M	-15.94M	-32.16M	9.52M	-3.25M	-6.63M	129K
Pretax Income+	-10.89M	-18.44M	-107.25M	980.32K	52.3M	44.09M	23.08M	14.99M	-12.01M	-8.49M
Pretax Margin %	-0.92%	-1.1%	-1%	0.01%	0.28%	0.21%	0.12%	0.07%	-0.05%	-0.03%
Income Tax+	851.68K	0	-11.33M	-27.61M	11.75M	6.35M	7.08M	1.31M	-1.46M	3.35M
Effective Tax Rate %	1%	1%	0.89%	29.16%	0.78%	0.86%	0.69%	0.91%	0.88%	1.39%
Net Income+	-10.89M	-18.44M	-95.92M	28.59M	40.56M	37.75M	16M	13.67M	-10.55M	-11.84M
Net Margin %	-0.92%	-1.1%	-0.89%	0.18%	0.21%	0.18%	0.08%	0.07%	-0.04%	-0.04%
Net Income Growth %	-0.55%	-0.69%	-4.2%	1.3%	0.42%	-0.07%	-0.58%	-0.15%	-1.77%	-0.12%
Net Income (Continuing)	-10.89M	-18.44M	-91.47M	28.59M	40.56M	37.75M	16M	13.67M	-10.55M	-11.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.35	-1.54	0.35	0.48	0.47	0.18	0.16	-0.14	-0.17
EPS Growth %	-0.57%	-0.59%	-3.4%	1.23%	0.37%	-0.02%	-0.62%	-0.11%	-1.88%	-0.21%
EPS (Basic)	-0.22	-0.35	-1.54	0.35	0.52	0.47	0.20	0.17	-0.14	-0.17
Diluted Shares Outstanding	51.09M	51.92M	62.55M	81.69M	84.19M	80.98M	87.64M	84.28M	65.7M	68.92M
Basic Shares Outstanding	51.09M	51.92M	62.55M	81.69M	84.19M	79.88M	87.64M	82.54M	65.7M	68.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.86M	65.41M	105.87M	132.05M	119.44M	215.47M	249.44M	277.5M	316.34M	278.44M
Cash & Short-Term Investments	34.6M	33.54M	70.37M	91.87M	74.35M	167.94M	191.92M	207.34M	213.42M	167.89M
Cash Only	34.6M	33.54M	70.37M	91.87M	74.35M	167.94M	191.92M	207.34M	61.74M	54.94M
Short-Term Investments	0	0	0	0	0	0	0	0	151.68M	112.95M
Accounts Receivable	3.27M	11.97M	12.22M	18.3M	28.86M	19.25M	27.59M	25.33M	42.62M	50.17M
Days Sales Outstanding	100.89	261.82	41.47	43.22	55.63	33.11	50.64	44.97	63.41	61.62
Inventory	17.74M	18.87M	22M	19.81M	16.22M	17.32M	27.31M	42.33M	56.76M	55.72M
Days Inventory Outstanding	1.23K	1.4K	537.72	284.94	247.47	268.55	471.49	879.68	821.73	574.57
Other Current Assets	227K	974K	1.29M	1.81M	-2.28M	7.67M	227K	213K	0	0
Total Non-Current Assets+	7.2M	67.93M	93.5M	113.39M	136.48M	127.08M	147.87M	148.3M	146.51M	121.55M
Property, Plant & Equipment	6.19M	6.36M	9.88M	9.61M	16.3M	17.73M	33.16M	39.15M	33.47M	23.3M
Fixed Asset Turnover	1.91x	2.63x	10.88x	16.08x	11.62x	11.97x	6.00x	5.25x	7.33x	12.76x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	791.55K	59.61M	67.94M	59.98M	79.4M	72.55M	83.83M	75.12M	71.27M	61.04M
Long-Term Investments	0	0	2.75M	2.29M	6.18M	5.83M	8.65M	9.73M	10.4M	4.23M
Other Non-Current Assets	218.66K	1.97M	1.6M	1.38M	2.54M	30.98M	1.01M	1.33M	1.62M	2.43M
Total Assets+	63.06M	133.34M	199.38M	245.45M	255.91M	342.55M	397.31M	425.8M	462.85M	399.99M
Asset Turnover	0.19x	0.13x	0.54x	0.63x	0.74x	0.62x	0.50x	0.48x	0.53x	0.74x
Asset Growth %	-0.07%	1.11%	0.5%	0.23%	0.04%	0.34%	0.16%	0.07%	0.09%	-0.14%
Total Current Liabilities+	14.73M	54.03M	70.22M	94.49M	114.25M	62.91M	46.77M	59.7M	77.97M	73.8M
Accounts Payable	1.11M	5.94M	11.31M	7.6M	40.65M	11.03M	7.6M	8.75M	16.02M	10.1M
Days Payables Outstanding	77.26	440.53	276.57	109.3	620.02	170.99	131.19	181.92	231.95	104.17
Short-Term Debt	3.05M	26.14M	26.87M	40.31M	51.13M	1.67M	1.88M	1.77M	1.82M	4.25M
Deferred Revenue (Current)	1000K	991.75K	964.56K	915.12K	0	0	0	0	0	0
Other Current Liabilities	7.97M	20.98M	35.29M	46.32M	-10.55M	21.26M	0	0	0	3.28M
Current Ratio	3.79x	1.21x	1.51x	1.40x	1.05x	3.43x	5.33x	4.65x	4.06x	3.77x
Quick Ratio	2.59x	0.86x	1.19x	1.19x	0.90x	3.15x	4.75x	3.94x	3.33x	3.02x
Cash Conversion Cycle	1.26K	1.22K	302.62	218.86	-316.92	130.67	390.93	742.73	653.18	532.02
Total Non-Current Liabilities+	22.26M	50.42M	106.61M	80.32M	24.27M	129.48M	157.63M	161.46M	166.1M	105.12M
Long-Term Debt	11.76M	42.48M	70.98M	42.63M	0	122.57M	139.01M	131.62M	136.6M	78.15M
Capital Lease Obligations	798K	629.97K	467.88K	187.6K	4.89M	6.74M	18.46M	29.84M	29.51M	26.97M
Deferred Tax Liabilities	0	0	0	99.52K	0	0	0	0	0	0
Other Non-Current Liabilities	1.17M	2.44M	33.4M	36.74M	19.38M	173.54K	165K	0	0	0
Total Liabilities	37M	104.45M	176.82M	174.81M	138.53M	192.39M	204.4M	221.16M	244.07M	178.92M
Total Debt+	17.35M	70.88M	97.53M	83.42M	58.2M	132.58M	161.76M	166.69M	171.54M	112.31M
Net Debt	-17.25M	37.34M	27.16M	-8.44M	-16.15M	-35.36M	-30.16M	-40.65M	109.8M	57.37M
Debt / Equity	0.67x	2.45x	4.32x	1.18x	0.50x	0.88x	0.84x	0.81x	0.78x	0.51x
Debt / EBITDA	-	-	3.21x	1.64x	0.79x	1.57x	4.88x	5.31x	16.28x	15.08x
Net Debt / EBITDA	-	-	0.89x	-0.17x	-0.22x	-0.42x	-0.91x	-1.29x	10.42x	7.70x
Interest Coverage	-14.29x	-3.22x	1.24x	2.65x	5.11x	12.83x	2.20x	3.40x	-0.90x	-0.99x
Total Equity+	26.06M	28.89M	22.56M	70.64M	117.39M	150.16M	192.92M	204.64M	218.78M	221.06M
Equity Growth %	-0.28%	0.11%	-0.22%	2.13%	0.66%	0.28%	0.28%	0.06%	0.07%	0.01%
Book Value per Share	0.51	0.56	0.36	0.86	1.39	1.85	2.20	2.43	3.33	3.21
Total Shareholders' Equity	26.06M	28.89M	22.56M	70.64M	117.39M	150.16M	192.92M	204.64M	218.78M	221.06M
Common Stock	4.5M	4.79M	6.95M	7.11M	7.23M	5.99M	7.43M	7.51M	7.67M	7.77M
Retained Earnings	-288.35M	-293.45M	-427.42M	-381.65M	-340.71M	-221.85M	-273.17M	-256.43M	-265.26M	-275.49M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	72.16K	63.1K	-1.13M	1.88M	8.93M	0	3.4M	-8.74M	-2.06M	-209K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.95M	-10.52M	45.84M	46.19M	74.15M	83.63M	37.84M	22.46M	-17.3M	-1.79M
Operating CF Margin %	-1.52%	-0.63%	0.43%	0.3%	0.39%	0.39%	0.19%	0.11%	-0.07%	-0.01%
Operating CF Growth %	-1.8%	0.41%	5.36%	0.01%	0.61%	0.13%	-0.55%	-0.41%	-1.77%	0.9%
Net Income	-9.96M	-12.14M	26.29M	43.46M	52.3M	44.09M	23.08M	14.99M	-12.01M	-8.49M
Depreciation & Amortization	0	795.09K	4.1M	7.5M	5.8M	8.31M	19.61M	13.19M	15.93M	16.07M
Stock-Based Compensation	0	0	0	0	0	6.54M	9.06M	6.39M	9.25M	11.25M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-8M	78.88K	2.13M	1.22M	13.87M	28.6M	-8.94M	-11.72M	-13.51M	-10.55M
Working Capital Changes	0	741.45K	13.33M	-6M	2.17M	-3.92M	-4.96M	-387K	-16.96M	-10.07M
Change in Receivables	0	0	0	0	-7.8M	-7.04M	5.92M	2.36M	-18.54M	-6.78M
Change in Inventory	0	-1.8M	-471.48K	1.17M	4.24M	-4.93M	-6.15M	-15.02M	-14.43M	-503K
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-981.79K	-60.45M	-7.25M	-4.31M	-28.26M	-15.63M	-21.3M	5.32M	-129.39M	31.62M
Capital Expenditures	-981.79K	-1.59M	-7.25M	-4.31M	-25.45M	-15.3M	-16.72M	-1.98M	-1.46M	-796K
CapEx % of Revenue	0.08%	0.1%	0.07%	0.03%	0.13%	0.07%	0.08%	0.01%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1K	0	0	0	21.28M	0
Cash from Financing+	15.7M	70.81M	-3.91M	-20.55M	-63.47M	60.69M	-27.95M	-4.98M	-1.04M	-34.41M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	15.04M	496.4K	-4.62M	-12.57M	-29.19M	-25.51M	-29.45M	-3.95M	3M	-19K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.94M	-12.11M	38.59M	41.87M	48.7M	68.33M	21.13M	20.48M	-18.77M	-2.59M
FCF Margin %	-1.6%	-0.73%	0.36%	0.27%	0.26%	0.32%	0.11%	0.1%	-0.08%	-0.01%
FCF Growth %	-1.87%	0.36%	4.19%	0.09%	0.16%	0.4%	-0.69%	-0.03%	-1.92%	0.86%
FCF per Share	-0.37	-0.23	0.62	0.51	0.58	0.84	0.24	0.24	-0.29	-0.04
FCF Conversion (FCF/Net Income)	1.65x	0.57x	-0.48x	1.62x	1.83x	2.22x	2.37x	1.64x	1.64x	0.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-34.92%	-67.12%	-372.93%	61.36%	43.14%	28.22%	9.33%	6.88%	-4.98%	-5.38%
Return on Invested Capital (ROIC)	-384.93%	-24.26%	34.01%	58.25%	62.64%	52.95%	7.33%	8.37%	-1.64%	-2.13%
Gross Margin	55.67%	70.5%	86.11%	83.59%	87.37%	88.91%	89.37%	91.46%	89.72%	88.09%
Net Margin	-91.96%	-110.48%	-89.22%	18.5%	21.41%	17.79%	8.04%	6.65%	-4.3%	-3.98%
Debt / Equity	0.67x	2.45x	4.32x	1.18x	0.50x	0.88x	0.84x	0.81x	0.78x	0.51x
Interest Coverage	-14.29x	-3.22x	1.24x	2.65x	5.11x	12.83x	2.20x	3.40x	-0.90x	-0.99x
FCF Conversion	1.65x	0.57x	-0.48x	1.62x	1.83x	2.22x	2.37x	1.64x	1.64x	0.15x
Revenue Growth	-54.05%	41.01%	544.06%	43.77%	22.52%	12.03%	-6.27%	3.39%	19.3%	21.15%

Revenue by Geography

	2020	2021	2022	2023	2024
UNITED STATES	177.39M	-	-	239.11M	287.15M
UNITED STATES Growth	-	-	-	-	20.09%
Europe	7.21M	4.93M	4.92M	-	-
Europe Growth	-	-31.53%	-0.18%	-	-
Rest Of The World, Excluding US And Europe	1.1M	519K	616K	-	-
Rest Of The World, Excluding US And Europe Growth	-	-52.86%	18.69%	-	-

Frequently Asked Questions

Growth & Financials

Pharming Group N.V. (PHAR) reported $362.3M in revenue for fiscal year 2024. This represents a 9220% increase from $3.9M in 2011.

Pharming Group N.V. (PHAR) grew revenue by 21.1% over the past year. This is strong growth.

Yes, Pharming Group N.V. (PHAR) is profitable, generating $0.4M in net income for fiscal year 2024 (-4.0% net margin).

Dividend & Returns

Pharming Group N.V. (PHAR) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.

Pharming Group N.V. (PHAR) generated $50.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Pharming Group N.V. (PHAR) 10-Year Financial Performance & Capital Metrics

PHAR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $297M +21.1%
EBITDA $7M -29.3%
Net Income -$12M -12.3%
EPS (Diluted) -0.17 -21.4%
Gross Margin 88.09% -1.8%
EBITDA Margin 2.51% -41.7%
Operating Margin -2.9% -32.1%
Net Margin -3.98% +7.3%
ROE -5.38% -8.1%
ROIC -2.13% -29.9%
Debt/Equity 0.51 -35.2%
Interest Coverage -0.99 -9.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.7%

5Y9.43%

3Y14.33%

TTM26.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM102.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM103.76%

ROCE

10Y Avg9.7%

5Y Avg8.35%

3Y Avg0.41%

Latest-2.42%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.84M	16.69M	107.52M	154.58M	189.39M	212.17M	198.87M	205.62M	245.32M	297.2M
Revenue Growth %	-0.54%	0.41%	5.44%	0.44%	0.23%	0.12%	-0.06%	0.03%	0.19%	0.21%
Cost of Goods Sold+	5.25M	4.93M	14.93M	25.37M	23.93M	23.54M	21.14M	17.56M	25.21M	35.4M
COGS % of Revenue	0.44%	0.3%	0.14%	0.16%	0.13%	0.11%	0.11%	0.09%	0.1%	0.12%
Gross Profit+	6.59M	11.77M	92.59M	129.2M	165.46M	188.63M	177.73M	188.06M	220.1M	261.8M
Gross Margin %	0.56%	0.7%	0.86%	0.84%	0.87%	0.89%	0.89%	0.91%	0.9%	0.88%
Gross Profit Growth %	-0.69%	0.79%	6.87%	0.4%	0.28%	0.14%	-0.06%	0.06%	0.17%	0.19%
Operating Expenses+	20.62M	23.91M	66.3M	85.74M	97.22M	112.38M	164.17M	169.83M	225.49M	270.42M
OpEx % of Revenue	1.74%	1.43%	0.62%	0.55%	0.51%	0.53%	0.83%	0.83%	0.92%	0.91%
Selling, General & Admin	5.28M	8.07M	44.86M	53.49M	55.88M	65M	48.13M	68.85M	87.5M	99.22M
SG&A % of Revenue	0.45%	0.48%	0.42%	0.35%	0.3%	0.31%	0.24%	0.33%	0.36%	0.33%
Research & Development	15.5M	16.18M	22.38M	33.04M	31.79M	38.52M	70.37M	52.53M	68.91M	83.15M
R&D % of Revenue	1.31%	0.97%	0.21%	0.21%	0.17%	0.18%	0.35%	0.26%	0.28%	0.28%
Other Operating Expenses	-147K	-335K	-790K	-684K	9.55M	8.86M	45.67M	48.44M	69.08M	88.06M
Operating Income+	-14.03M	-12.14M	26.29M	43.46M	68.25M	76.26M	13.56M	18.23M	-5.39M	-8.62M
Operating Margin %	-1.19%	-0.73%	0.24%	0.28%	0.36%	0.36%	0.07%	0.09%	-0.02%	-0.03%
Operating Income Growth %	-5.01%	0.14%	3.17%	0.65%	0.57%	0.12%	-0.82%	0.34%	-1.3%	-0.6%
EBITDA+	-14.75M	-11.34M	30.38M	50.96M	74.05M	84.57M	33.17M	31.42M	10.54M	7.45M
EBITDA Margin %	-1.25%	-0.68%	0.28%	0.33%	0.39%	0.4%	0.17%	0.15%	0.04%	0.03%
EBITDA Growth %	-4.97%	0.23%	3.68%	0.68%	0.45%	0.14%	-0.61%	-0.05%	-0.66%	-0.29%
D&A (Non-Cash Add-back)	-716.11K	795.09K	4.1M	7.5M	5.8M	8.31M	19.61M	13.19M	15.93M	16.07M
EBIT	-9.9M	-14.67M	-80.43M	17.35M	65.66M	50.04M	29.17M	20.34M	-6.05M	245K
Net Interest Income+	-851.68K	-6.38M	-56.53M	-16.35M	-12.22M	-5.3M	-6.12M	-5.27M	-2.44M	-3.02M
Interest Income	130.1K	5.26K	3.6K	20.59K	1.13M	715K	52.92K	85K	3.53M	5.72M
Interest Expense	981.78K	3.77M	21.28M	16.37M	13.35M	5.94M	6.18M	5.36M	5.96M	8.74M
Other Income/Expense	4.07M	-6.31M	-129.09M	-37.01M	-15.94M	-32.16M	9.52M	-3.25M	-6.63M	129K
Pretax Income+	-10.89M	-18.44M	-107.25M	980.32K	52.3M	44.09M	23.08M	14.99M	-12.01M	-8.49M
Pretax Margin %	-0.92%	-1.1%	-1%	0.01%	0.28%	0.21%	0.12%	0.07%	-0.05%	-0.03%
Income Tax+	851.68K	0	-11.33M	-27.61M	11.75M	6.35M	7.08M	1.31M	-1.46M	3.35M
Effective Tax Rate %	1%	1%	0.89%	29.16%	0.78%	0.86%	0.69%	0.91%	0.88%	1.39%
Net Income+	-10.89M	-18.44M	-95.92M	28.59M	40.56M	37.75M	16M	13.67M	-10.55M	-11.84M
Net Margin %	-0.92%	-1.1%	-0.89%	0.18%	0.21%	0.18%	0.08%	0.07%	-0.04%	-0.04%
Net Income Growth %	-0.55%	-0.69%	-4.2%	1.3%	0.42%	-0.07%	-0.58%	-0.15%	-1.77%	-0.12%
Net Income (Continuing)	-10.89M	-18.44M	-91.47M	28.59M	40.56M	37.75M	16M	13.67M	-10.55M	-11.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.35	-1.54	0.35	0.48	0.47	0.18	0.16	-0.14	-0.17
EPS Growth %	-0.57%	-0.59%	-3.4%	1.23%	0.37%	-0.02%	-0.62%	-0.11%	-1.88%	-0.21%
EPS (Basic)	-0.22	-0.35	-1.54	0.35	0.52	0.47	0.20	0.17	-0.14	-0.17
Diluted Shares Outstanding	51.09M	51.92M	62.55M	81.69M	84.19M	80.98M	87.64M	84.28M	65.7M	68.92M
Basic Shares Outstanding	51.09M	51.92M	62.55M	81.69M	84.19M	79.88M	87.64M	82.54M	65.7M	68.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.86M	65.41M	105.87M	132.05M	119.44M	215.47M	249.44M	277.5M	316.34M	278.44M
Cash & Short-Term Investments	34.6M	33.54M	70.37M	91.87M	74.35M	167.94M	191.92M	207.34M	213.42M	167.89M
Cash Only	34.6M	33.54M	70.37M	91.87M	74.35M	167.94M	191.92M	207.34M	61.74M	54.94M
Short-Term Investments	0	0	0	0	0	0	0	0	151.68M	112.95M
Accounts Receivable	3.27M	11.97M	12.22M	18.3M	28.86M	19.25M	27.59M	25.33M	42.62M	50.17M
Days Sales Outstanding	100.89	261.82	41.47	43.22	55.63	33.11	50.64	44.97	63.41	61.62
Inventory	17.74M	18.87M	22M	19.81M	16.22M	17.32M	27.31M	42.33M	56.76M	55.72M
Days Inventory Outstanding	1.23K	1.4K	537.72	284.94	247.47	268.55	471.49	879.68	821.73	574.57
Other Current Assets	227K	974K	1.29M	1.81M	-2.28M	7.67M	227K	213K	0	0
Total Non-Current Assets+	7.2M	67.93M	93.5M	113.39M	136.48M	127.08M	147.87M	148.3M	146.51M	121.55M
Property, Plant & Equipment	6.19M	6.36M	9.88M	9.61M	16.3M	17.73M	33.16M	39.15M	33.47M	23.3M
Fixed Asset Turnover	1.91x	2.63x	10.88x	16.08x	11.62x	11.97x	6.00x	5.25x	7.33x	12.76x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	791.55K	59.61M	67.94M	59.98M	79.4M	72.55M	83.83M	75.12M	71.27M	61.04M
Long-Term Investments	0	0	2.75M	2.29M	6.18M	5.83M	8.65M	9.73M	10.4M	4.23M
Other Non-Current Assets	218.66K	1.97M	1.6M	1.38M	2.54M	30.98M	1.01M	1.33M	1.62M	2.43M
Total Assets+	63.06M	133.34M	199.38M	245.45M	255.91M	342.55M	397.31M	425.8M	462.85M	399.99M
Asset Turnover	0.19x	0.13x	0.54x	0.63x	0.74x	0.62x	0.50x	0.48x	0.53x	0.74x
Asset Growth %	-0.07%	1.11%	0.5%	0.23%	0.04%	0.34%	0.16%	0.07%	0.09%	-0.14%
Total Current Liabilities+	14.73M	54.03M	70.22M	94.49M	114.25M	62.91M	46.77M	59.7M	77.97M	73.8M
Accounts Payable	1.11M	5.94M	11.31M	7.6M	40.65M	11.03M	7.6M	8.75M	16.02M	10.1M
Days Payables Outstanding	77.26	440.53	276.57	109.3	620.02	170.99	131.19	181.92	231.95	104.17
Short-Term Debt	3.05M	26.14M	26.87M	40.31M	51.13M	1.67M	1.88M	1.77M	1.82M	4.25M
Deferred Revenue (Current)	1000K	991.75K	964.56K	915.12K	0	0	0	0	0	0
Other Current Liabilities	7.97M	20.98M	35.29M	46.32M	-10.55M	21.26M	0	0	0	3.28M
Current Ratio	3.79x	1.21x	1.51x	1.40x	1.05x	3.43x	5.33x	4.65x	4.06x	3.77x
Quick Ratio	2.59x	0.86x	1.19x	1.19x	0.90x	3.15x	4.75x	3.94x	3.33x	3.02x
Cash Conversion Cycle	1.26K	1.22K	302.62	218.86	-316.92	130.67	390.93	742.73	653.18	532.02
Total Non-Current Liabilities+	22.26M	50.42M	106.61M	80.32M	24.27M	129.48M	157.63M	161.46M	166.1M	105.12M
Long-Term Debt	11.76M	42.48M	70.98M	42.63M	0	122.57M	139.01M	131.62M	136.6M	78.15M
Capital Lease Obligations	798K	629.97K	467.88K	187.6K	4.89M	6.74M	18.46M	29.84M	29.51M	26.97M
Deferred Tax Liabilities	0	0	0	99.52K	0	0	0	0	0	0
Other Non-Current Liabilities	1.17M	2.44M	33.4M	36.74M	19.38M	173.54K	165K	0	0	0
Total Liabilities	37M	104.45M	176.82M	174.81M	138.53M	192.39M	204.4M	221.16M	244.07M	178.92M
Total Debt+	17.35M	70.88M	97.53M	83.42M	58.2M	132.58M	161.76M	166.69M	171.54M	112.31M
Net Debt	-17.25M	37.34M	27.16M	-8.44M	-16.15M	-35.36M	-30.16M	-40.65M	109.8M	57.37M
Debt / Equity	0.67x	2.45x	4.32x	1.18x	0.50x	0.88x	0.84x	0.81x	0.78x	0.51x
Debt / EBITDA	-	-	3.21x	1.64x	0.79x	1.57x	4.88x	5.31x	16.28x	15.08x
Net Debt / EBITDA	-	-	0.89x	-0.17x	-0.22x	-0.42x	-0.91x	-1.29x	10.42x	7.70x
Interest Coverage	-14.29x	-3.22x	1.24x	2.65x	5.11x	12.83x	2.20x	3.40x	-0.90x	-0.99x
Total Equity+	26.06M	28.89M	22.56M	70.64M	117.39M	150.16M	192.92M	204.64M	218.78M	221.06M
Equity Growth %	-0.28%	0.11%	-0.22%	2.13%	0.66%	0.28%	0.28%	0.06%	0.07%	0.01%
Book Value per Share	0.51	0.56	0.36	0.86	1.39	1.85	2.20	2.43	3.33	3.21
Total Shareholders' Equity	26.06M	28.89M	22.56M	70.64M	117.39M	150.16M	192.92M	204.64M	218.78M	221.06M
Common Stock	4.5M	4.79M	6.95M	7.11M	7.23M	5.99M	7.43M	7.51M	7.67M	7.77M
Retained Earnings	-288.35M	-293.45M	-427.42M	-381.65M	-340.71M	-221.85M	-273.17M	-256.43M	-265.26M	-275.49M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	72.16K	63.1K	-1.13M	1.88M	8.93M	0	3.4M	-8.74M	-2.06M	-209K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.95M	-10.52M	45.84M	46.19M	74.15M	83.63M	37.84M	22.46M	-17.3M	-1.79M
Operating CF Margin %	-1.52%	-0.63%	0.43%	0.3%	0.39%	0.39%	0.19%	0.11%	-0.07%	-0.01%
Operating CF Growth %	-1.8%	0.41%	5.36%	0.01%	0.61%	0.13%	-0.55%	-0.41%	-1.77%	0.9%
Net Income	-9.96M	-12.14M	26.29M	43.46M	52.3M	44.09M	23.08M	14.99M	-12.01M	-8.49M
Depreciation & Amortization	0	795.09K	4.1M	7.5M	5.8M	8.31M	19.61M	13.19M	15.93M	16.07M
Stock-Based Compensation	0	0	0	0	0	6.54M	9.06M	6.39M	9.25M	11.25M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-8M	78.88K	2.13M	1.22M	13.87M	28.6M	-8.94M	-11.72M	-13.51M	-10.55M
Working Capital Changes	0	741.45K	13.33M	-6M	2.17M	-3.92M	-4.96M	-387K	-16.96M	-10.07M
Change in Receivables	0	0	0	0	-7.8M	-7.04M	5.92M	2.36M	-18.54M	-6.78M
Change in Inventory	0	-1.8M	-471.48K	1.17M	4.24M	-4.93M	-6.15M	-15.02M	-14.43M	-503K
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-981.79K	-60.45M	-7.25M	-4.31M	-28.26M	-15.63M	-21.3M	5.32M	-129.39M	31.62M
Capital Expenditures	-981.79K	-1.59M	-7.25M	-4.31M	-25.45M	-15.3M	-16.72M	-1.98M	-1.46M	-796K
CapEx % of Revenue	0.08%	0.1%	0.07%	0.03%	0.13%	0.07%	0.08%	0.01%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1K	0	0	0	21.28M	0
Cash from Financing+	15.7M	70.81M	-3.91M	-20.55M	-63.47M	60.69M	-27.95M	-4.98M	-1.04M	-34.41M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	15.04M	496.4K	-4.62M	-12.57M	-29.19M	-25.51M	-29.45M	-3.95M	3M	-19K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.94M	-12.11M	38.59M	41.87M	48.7M	68.33M	21.13M	20.48M	-18.77M	-2.59M
FCF Margin %	-1.6%	-0.73%	0.36%	0.27%	0.26%	0.32%	0.11%	0.1%	-0.08%	-0.01%
FCF Growth %	-1.87%	0.36%	4.19%	0.09%	0.16%	0.4%	-0.69%	-0.03%	-1.92%	0.86%
FCF per Share	-0.37	-0.23	0.62	0.51	0.58	0.84	0.24	0.24	-0.29	-0.04
FCF Conversion (FCF/Net Income)	1.65x	0.57x	-0.48x	1.62x	1.83x	2.22x	2.37x	1.64x	1.64x	0.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-34.92%	-67.12%	-372.93%	61.36%	43.14%	28.22%	9.33%	6.88%	-4.98%	-5.38%
Return on Invested Capital (ROIC)	-384.93%	-24.26%	34.01%	58.25%	62.64%	52.95%	7.33%	8.37%	-1.64%	-2.13%
Gross Margin	55.67%	70.5%	86.11%	83.59%	87.37%	88.91%	89.37%	91.46%	89.72%	88.09%
Net Margin	-91.96%	-110.48%	-89.22%	18.5%	21.41%	17.79%	8.04%	6.65%	-4.3%	-3.98%
Debt / Equity	0.67x	2.45x	4.32x	1.18x	0.50x	0.88x	0.84x	0.81x	0.78x	0.51x
Interest Coverage	-14.29x	-3.22x	1.24x	2.65x	5.11x	12.83x	2.20x	3.40x	-0.90x	-0.99x
FCF Conversion	1.65x	0.57x	-0.48x	1.62x	1.83x	2.22x	2.37x	1.64x	1.64x	0.15x
Revenue Growth	-54.05%	41.01%	544.06%	43.77%	22.52%	12.03%	-6.27%	3.39%	19.3%	21.15%

Revenue by Geography

	2020	2021	2022	2023	2024
UNITED STATES	177.39M	-	-	239.11M	287.15M
UNITED STATES Growth	-	-	-	-	20.09%
Europe	7.21M	4.93M	4.92M	-	-
Europe Growth	-	-31.53%	-0.18%	-	-
Rest Of The World, Excluding US And Europe	1.1M	519K	616K	-	-
Rest Of The World, Excluding US And Europe Growth	-	-52.86%	18.69%	-	-

Frequently Asked Questions

Growth & Financials

Pharming Group N.V. (PHAR) reported $362.3M in revenue for fiscal year 2024. This represents a 9220% increase from $3.9M in 2011.

Pharming Group N.V. (PHAR) grew revenue by 21.1% over the past year. This is strong growth.

Yes, Pharming Group N.V. (PHAR) is profitable, generating $0.4M in net income for fiscal year 2024 (-4.0% net margin).

Dividend & Returns

Pharming Group N.V. (PHAR) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.

Pharming Group N.V. (PHAR) generated $50.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.